RxDoctor Payments Data

Thieu Nguyen, MD

Cardiology · Houston, TXNPI 1609967165

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,478 of the $5,413 with a category attached, or 64.2%. 17 manufacturers reported payments, led by Boston Scientific at 47.2% of the total. Reporting peaked in 2023 at $2,817 and has fallen 89.7% since, to $291 in 2025.

$5,413in general payments, 2019–2025

Across 102 payments — averaging $53.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Johnson & Johnson$945
  • E.r. Squibb & Sons, L.L.C.$382
  • Abbott$299
  • AstraZeneca$269
  • Abiomed$149
  • plus $816 from 11 others

What the payments were for

  • Travel & lodging$1,93536%
  • Food & beverage$3,47864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,413 in reported general payments places this provider in the 80th percentile of 33 cardiology providers in Texas.

See all cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$159,981
Medicare patients
218
Services billed
1,859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$242,207
XareltoRivaroxaban182$201,812
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc1,063$152,905
Desonide707$114,439
VascepaIcosapent Ethyl118$88,664
Ranolazine ErRanolazine305$52,786
FarxigaDapagliflozin Propanediol31$46,153
EntrestoSacubitril/Valsartan38$38,631
Amiodarone Hcl90$9,425
Icosapent Ethyl26$8,716
Metoprolol Succinate343$3,612
Flecainide Acetate47$2,339
Omega-3 Acid Ethyl Esters27$1,034
ClopidogrelClopidogrel Bisulfate124$1,030
Atorvastatin Calcium138$720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$242,207195 claims
Johnson & JohnsonXarelto$945$201,812182 claims
AstraZenecaFarxiga$269$46,15331 claims
NovartisEntresto$24$38,63138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 cardiology providers in Texas.

Other cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →